Federal record
FDA Warning Letter issued February 20, 2026 · As of October 2026, Vial did not find a close-out letter in FDA records. Read the FDA letter →
We're providing this information based on regulatory filings Vial reviewed as of 2026-10-07. Regulatory status can change, and actions may be resolved or closed out. Confirm current status with the issuing agency: FDA.gov →
SkinnyRx
Reviewed by Vial Editorial · October 1, 2026
CA · Serves 47 states
Is this your company? Claim this profile.
SkinnyRx is an online clinic available in 47 states. The FDA issued a warning letter involving SkinnyRx on February 20, 2026, with no close-out letter found resolving it. Pricing starts at about $299 per month, though total cost should be confirmed before signing up.
What they offerOnline Clinic
Why this score?
The Vial Score measures how much of this provider's public record Vial could confirm, and how clearly the provider discloses it. It does not measure quality of care.
| 85-100 | High Confidence |
| 70-84 | Well Documented |
| 50-69 | Limited Confidence |
| 0-49 | Flagged |
SkinnyRx scores 38, in the Flagged band. The score moves when the public record changes. For SkinnyRx, the item most likely to move it: LegitScript certification.
Payment never changes a score.
4 of 5 checks complete. The remaining checks have not been run yet. Missing checks reduce how complete the profile is. They are not a finding by themselves.
Score history
- 38September 2026Record updated
- 64July 2026Record updated
- 57June 2026Record updated
- 64June 2026Record updated
- 78June 2026Record updated
- 56June 2026Vial scoring update
What we found on SkinnyRx
We reviewed FDA enforcement records, OIG exclusions, DEA registration, and HIPAA breach records.
The FDA issued a warning letter involving SkinnyRx on February 20, 2026. We have not found a close-out letter resolving it as of our last check (October 7, 2026); read the details below before going further. The company serves 47 states and publicly identifies its physicians. We could not independently verify a third-party certification or accreditation as of October 2026.
Why this score: 4 of 5 checks complete. Each links to the public source it was verified against.
A check we haven’t completed yet is not a mark against this provider. It just means we’re still sourcing that record. The score reflects what we’ve confirmed so far, and updates as more checks come in.
Vial describes the record, not the provider. This is not a medical recommendation or endorsement. Last reviewed October 1, 2026.
Our take
Vial EditorialBased on the records and public materials we reviewed.
SkinnyRx is a Sacramento telehealth service selling compounded GLP-1 medication. Injectable semaglutide and tirzepatide are $99 for the first month. Their product pages don't show the renewal price. The pricing file their site loads lists $249 for semaglutide and $299 for tirzepatide, which we couldn't confirm at checkout. Multi-month bundles are non-refundable, and renewals can be charged up to five days early.
The FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx on February 20, 2026. We found no close-out letter for it in FDA records checked on September 23, 2026. The letter is published at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026. They name their medical director, Sajad Zalzala, M.D., but not their pharmacies. Their terms say compounded products aren't sold in Alabama, Louisiana or Mississippi. Trustpilot reviewers give them 4.8 from 5,340 reviews. The Better Business Bureau lists 156 complaints in three years, many about charges after cancelling.
What it costs
Shown on skinnyrx.com on September 21, 2026: compounded injectable semaglutide and tirzepatide at $99 for the first month, semaglutide tablets at $149, tirzepatide tablets at $199. No ongoing price appears on the product pages. The pricing file the site loads lists monthly renewals of $249 (injectable semaglutide) and $299 (injectable tirzepatide and both tablets). We could not confirm these at checkout, because checkout sits behind a medical intake. On those figures, a year on the monthly plan is $99 + 11 x $249 = $2,838 for semaglutide and $99 + 11 x $299 = $3,388 for tirzepatide. The same file lists 12-month plans at $190.65 a month for semaglutide (x 12 = $2,287.80) and $214.50 for tirzepatide (x 12 = $2,574), also not confirmed at checkout. We could not confirm whether those are billed in one payment, but BBB complaints describe single charges above $2,100. The company's policy says bundled subscriptions are non-refundable. The price includes clinician review, messaging with the care team and free overnight shipping. Labs are not mentioned. You get a full refund if you cancel before the clinician review or are not approved. After that, there are no refunds for part-used periods. The terms say you must cancel at least five days before the renewal date, and renewals can be charged up to five days early. Cancelling a discounted term early can claw back the discount. A 90-day money-back guarantee exists, but it requires weekly weight and dose logging in the app, no weight loss at all, and a claim within 14 days. FSA and HSA cards are accepted. The company does not take insurance, Medicare or Medicaid. Before paying, get in writing the exact amount charged today, the renewal amount and the renewal date.
Sources: skinnyrx.com · skinnyrx.com · skinnyrx.com · skinnyrx.com · skinnyrx.com · skinnyrx.com · glp1drugs.org · clearmetabolic.com · vaccinealliance.org · finance.yahoo.com · getvial.com
What patients report
The two main review sites tell opposite stories. Trustpilot shows 4.8 out of 5 from 5,340 reviews, 91% five star and 4% one star. The profile is claimed and the company replies to 97% of negative reviews. We opened it on September 21, 2026 and the newest review on the copy we saw was dated August 31, 2026. The BBB profile, seen September 21, 2026, shows a B rating, not accredited, with 156 complaints in three years and 104 closed in the last 12 months. The largest complaint groups are product issues (54), service issues (51) and sales or advertising issues (20). Praise centres on helpful support staff, often named, a quick intake and fast shipping. Complaints centre on charges after a cancellation request, cancelling that requires a phone call, large single charges people did not expect, refused refunds, late or warm shipments and no results. What the pattern means: sign-up and support calls go well for most people, and the trouble starts when someone tries to stop paying. Know your renewal date and cancel early, in writing.
Sources: trustpilot.com · bbb.org · bbb.org · fda.gov
What the record means
Vial scores SkinnyRx 38 out of 100, Flagged.
The FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx on February 20, 2026. We found no close-out letter for it in FDA records checked on September 16, 2026. The letter is published at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026. We found no other federal action in records checked September 16, 2026, and no FTC, state attorney general or licensing board action naming SkinnyRx in searches run September 21, 2026. LegitScript certification has not been checked. The company states that it uses partner 503A pharmacies licensed by state boards. It does not name them, so you cannot look up who compounds the medication. The company states that its providers are US based and licensed, and its site names Sajad Zalzala, M.D. as Medical Director. His license has not been checked. The company's terms, updated May 20, 2026, state that branded products may be available in all states and that compounded products are not available in Alabama, Louisiana and Mississippi. That list has not been checked against a second source. The company states that compounded drugs are not FDA approved. Ask which pharmacy will fill your order before you pay.
Worth asking before you choose
Ask these before you sign up.
- 1What changed after the FDA warning letter?
- 2Has FDA issued a close-out letter?
- 3Are you operating as a 503A pharmacy or a 503B outsourcing facility?
- 4Which states are you licensed to ship to?
- 5Can you provide current state pharmacy license details?
See all 5 questionsShow fewer
Screenshot these or show your doctor: they’re the same questions Vial would ask.
Compare record details
Brightside has no federal action found; SkinnyRx has an FDA warning letter with no close-out letter found.
SkinnyRx scores 38, Brightside scores 78.
| SkinnyRx | Brightside | |
|---|---|---|
| Federal actions | Confirmed | None found |
| Vial Score | 38/100 | 78/100 |
| LegitScript certified | No | No |
| States served | 47 states | Not checked |
What Vial measures, and what we don’t
We evaluate public records: federal enforcement history, registrations, certifications, and how transparent a provider is about its clinicians, pharmacies, and pricing. We don’t score bedside manner, clinical outcomes, or customer satisfaction, and we don’t collect user reviews.
Other telehealth providers in Vial
Other Online clinics in Vial’s directory. Open a profile, or compare side by side.
See 2 more alternativesShow fewer
Not sure where to start?Answer a few questions and we’ll narrow the directory to providers that fit.
Find your providerAppears on: Tirzepatide Cost in 2026
Appears on: Semaglutide Cost in 2026
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.